PatientsVille.com Logo


Incb018424 Medical Research Studies

Up-to-date List of Incb018424 Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Incb018424 Medical Research Studies

Rank Status Study
1 Recruiting Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
Conditions: Cystic Fibrosis;   Allergic Bronchopulmonary Aspergillosis;   A. Fumigatus
Intervention: Dietary Supplement: cholecalciferol (Vitamin D3)
Outcome Measures: Aspergillus induced IL-13 responses in CD4+ T-cells;   Total IgE, Aspergillus specific IgE and IgG levels, vitamin D levels, FEV1, cytokine production by Aspergillus stimulated peripheral blood T cells, urine calcium/creatinine ratio
2 Recruiting Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis
Condition: Allergic Bronchopulmonary Aspergillosis
Interventions: Drug: Prednisolone;   Drug: Voriconazole
Outcome Measures: Response rates in the two groups;   Relapse rates in the two groups;   Number of Participants with Adverse Events
3 Recruiting Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
Condition: Invasive Pulmonary Aspergillosis
Intervention: Device: Lateral Flow Device Test
Outcome Measure: Performance of the Lateral Flow Device Test for diagnosisng of invasive pulmonary aspergillosis in BAL fluids
4 Not yet recruiting CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
Condition: Invasive Pulmonary Aspergillosis
Intervention: Drug: Voriconazole
Outcome Measures: voriconazole trough level;   Overall mortality
5 Not yet recruiting Voriconazole for IPA in Chinese Patients With COPD
Conditions: Invasive Pulmonary Aspergillosis;   COPD
Intervention: Drug: Voriconazole
Outcome Measures: success rate of voriconazole antifungal treatment;   adverse reactions following voriconazole treatment
6 Unknown  Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
Condition: Invasive Pulmonary Aspergillosis
Intervention: Drug: Amphotericin B
Outcome Measure: invasive pulmonary aspergillosis
7 Recruiting Protocol TARC-ABPA
Condition: Allergic Broncho-Pulmonary Aspergillosis
Intervention: Other: Study of predictive factors
Outcome Measures: The rate of serum TARC;   Induced sputum eosinophils count;   The rate of Exhaled NO(FeNO50);   The rate of circulating T cells;   The rate of Aspf. specific serum IgG;   Correlation between markers;   Fungal exposure at home;   Clincal parameters;   Biological parameters;   Function parameters
8 Recruiting A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
Condition: Allergic Bronchopulmonary Aspergillosis
Interventions: Drug: Inhaled budesonide;   Drug: Inhaled amphotericin
Outcome Measures: Time to first relapse;   ACQ-7 scores between the two groups;   Number of asthma exacerbations requiring oral steroids;   Improvement in forced expiratory volume in the first second (FEV1);   Adverse effects of therapy in both the arms
9 Unknown  Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
Conditions: Cystic Fibrosis;   Allergic Bronchopulmonary Aspergillosis
Outcome Measures: To test the hypothesis that the white blood cells of CF patients with ABPA will demonstrate increased inflammatory cytokine expression in response to binding of A. fumigatus antigens compared to white blood cells from non-ABPA patients.;   To test the hypothesis that T cells from CF patients with ABPA will have decreased adaptive regulatory function;   To test the hypothesis that surface-bound TGF beta is critical for the development and maintenance of immune tolerance to A. fumigatus antigens
10 Recruiting Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
Conditions: Invasive Pulmonary Aspergillosis;   Chronic Obstructive Pulmonary Disease
Intervention: Drug: caspofungin
Outcome Measures: Global response (defined as both clinical and microbiologic success) at the end of intravenous therapy;   Assessment of Safety of Caspofungin for IPA Underlying COPD;   Global response to 2-week caspofungin therapy;   Factors such as severity of COPD, exposure to systemic corticosteroids,extended-spectrum antibiotics et al. affecting patients' response to caspofungin therapy;   Clinical response at Day 7 of treatment
11 Recruiting Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients
Conditions: Survival After IPA;   Risk Factors for IPA
Outcome Measures: death after 6 month;   death after 28 days
12 Unknown  Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration
Condition: Immunocompromised
Intervention: Procedure: Lung aspiration
Outcome Measure: The diagnostic rate of lung tissue Aspergillus galactomannan antigen detection compaired with serum Aspergillus galactomannan antigen detection
13 Unknown  Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
Condition: Allergic Bronchopulmonary Aspergillosis
Intervention: Drug: Glucocorticoids
Outcome Measures: Remission rates in the two groups at six weeks and three months;   Percentage decline in IgE levels at six weeks and three months;   Complete remission rates in the two groups;   Relapse rates in the two groups at six and 12 months after completion of treatment;   Treatment related adverse effects in the two groups
14 Recruiting Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
Condition: Allergic Bronchopulmonary Aspergillosis
Intervention: Drug: Liposomal amphotericin B (Ambisome®)
Outcome Measure: occurrence of first severe clinical exacerbation
15 Unknown  Application of an Electronic Nose in the Early Detection of ASpergillosis
Condition: Pulmonary Invasive Aspergillosis
Outcome Measure: accuracy with which the Cyranose can discriminate between patients with probable or proven invasive pulmonary aspergillosis and neutropenic controls with fever
16 Recruiting Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Conditions: Invasive Aspergillosis;   Pleural Effusion;   Immunosuppression
Outcome Measure: Test Sensitivity
17 Recruiting Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
Condition: Aspergillosis
Interventions: Drug: Posaconazole;   Drug: Voriconazole
Outcome Measures: Number of participants with an Adverse Event;   Percentage of participants successfully treated for Invasive Aspergillosis;   Percentage of participants successfully treated for Chronic Pulmonary Aspergillosis
18 Recruiting Clinical Impact of Fungal Domestic Environmental Exposure on COPD Patients
Conditions: COPD;   Pulmonary Fungal Diseases;   Environmental Exposure
Outcome Measure: Comparison of domestic mould exposure of colonized/sensitized and non colonized/non sensitized COPD patients.

These studies may lead to new treatments and are adding insight into Incb018424 etiology and treatment.

A major focus of Incb018424 research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Incb018424